What is the current size of monoclonal antibodies market?

The global monoclonal antibodies market size was reached at USD 226.63 billion in 2023 and it is expected to rake round USD 729.43 billion by 2033. Read More

What will be the CAGR of global monoclonal antibodies market?

The global monoclonal antibodies market is expected to drive growth at a CAGR of 12.2% from 2024 to 2033. Read More

Who are the major players operating in the monoclonal antibodies market?

The major players operating in the monoclonal antibodies market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc., Norvatis AG, Pfizer Inc., Thermofischer Scientific, Elililly and Company, Bristol-Myers Squibb Read More

Which are the driving factors of the monoclonal antibodies market?

The rising cases of cancer and other chronic diseases among the global population is expected to drive the demand for the monoclonal antibodies and foster the market growth during the forecast period. Read More

Which region will lead the global monoclonal antibodies market?

The North America region hit highest revenue share of 46.14% in 2023 and will lead the global monoclonal antibodies market. Read More

Monoclonal Antibodies Market Size, Share, and Trends 2024 to 2034

Monoclonal Antibodies Market (By Source: Humanized mAb, Human mAb, Murine mAb, Chimeric mAb; By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Others; By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy; By Production Methods: In Vivo, In Vitro) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033

Last Updated : June 2024
Report Code : 1735
Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Monoclonal Antibodies Market

5.1. COVID-19 Landscape: Monoclonal Antibodies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Monoclonal Antibodies Market, By Source

8.1. Monoclonal Antibodies Market, by Source, 2023-2032

8.1.1. Humanized mAb

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Human mAb

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Murine mAb

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Chimeric mAb

8.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Monoclonal Antibodies Market, By Indication

9.1. Ambulatory Surgical Center Market, by Indication, 2023-2032

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Autoimmune Diseases

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Inflammatory Diseases

9.1.3.1. Market Revenue and Forecast (2021-2032)

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast (2021-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Monoclonal Antibodies Market, By Distribution Channel

10.1. Monoclonal Antibodies Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacy

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Online Pharmacy

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Retail Pharmacy

10.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Monoclonal Antibodies Market, By Production Methods

11.1. Monoclonal Antibodies Market, by Production Methods, 2023-2032

11.1.1. In Vivo

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. In Vitro

11.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Monoclonal Antibodies Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Source (2021-2032)

12.1.2. Market Revenue and Forecast, by Indication (2021-2032)

12.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.1.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.1.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.1.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.7.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.7.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Source (2021-2032)

12.2.8.2. Market Revenue and Forecast, by Indication (2021-2032)

12.2.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.8.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.7.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.7.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Source (2021-2032)

12.3.8.2. Market Revenue and Forecast, by Indication (2021-2032)

12.3.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.8.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.7.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.7.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Source (2021-2032)

12.4.8.2. Market Revenue and Forecast, by Indication (2021-2032)

12.4.8.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.8.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Source (2021-2032)

12.5.5.2. Market Revenue and Forecast, by Indication (2021-2032)

12.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.5.4. Market Revenue and Forecast, by Production Methods (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Source (2021-2032)

12.5.6.2. Market Revenue and Forecast, by Indication (2021-2032)

12.5.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.6.4. Market Revenue and Forecast, by Production Methods (2021-2032)

Chapter 13. Company Profiles

13.1. Johnson & Johnson

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Merck

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. AbbVie

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Amgen

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GlaxoSmithKline plc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Norvatis AG

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Thermofischer Scientific

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Elililly and Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Bristol-Myers Squibb

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

We use cookies to improve your experience

Monoclonal Antibodies Market Size To Worth USD 729.43 Bn By 2033

List of Contents